Literature DB >> 27607436

Mixed Phenotype Acute Leukemia with t(12;17)(p13;q21)/TAF15-ZNF384 and Other Chromosome Abnormalities.

Katsuya Yamamoto1, Shinichiro Kawamoto, Yu Mizutani, Kimikazu Yakushijin, Tomoe Yamashita, Yuji Nakamachi, Seiji Kawano, Yoshitake Hayashi, Hiroshi Matsuoka, Hironobu Minami.   

Abstract

The t(12;17)(p13;q11∼21) translocation is a very rare but recurrent cytogenetic aberration observed predominantly in early pre-B acute lymphoblastic leukemia (ALL) with CD19+CD10-CD33+ phenotype. This translocation was shown to form a fusion gene between TAF15 at 17q12 and ZNF384 at 12p13. On the other hand, der(1;18)(q10;q10) has been detected as a rare unbalanced whole-arm translocation leading to trisomy 1q in myeloid malignancies. We describe here the first case of mixed phenotype acute leukemia (MPAL) with a t(12;17)(p13;q21)/TAF15-ZNF384, which also had der(1;18)(q10;q10) as an additional abnormality. A 74-year-old woman was diagnosed with MPAL, B/myeloid, because bone marrow blasts were positive for myeloperoxidase, CD19, and CD22. Chromosome analysis showed 46,XX, +1,der(1;18)(q10;q10),t(2;16)(q13;q13),t(12;17)(p13;q21). Expression of the TAF15-ZNF384 fusion transcript was confirmed: TAF15 exon 6 was fused in-frame to ZNF384 exon 3. This type of fusion gene has been reported in 1 acute myeloid leukemia case and 3 ALL cases. Thus, at present, it is difficult to find a specific association between the structure of the TAF15-ZNF384 fusion gene and the leukemia phenotype. The TAF15-ZNF384 fusion may occur in early common progenitor cells that could differentiate into both the myeloid and lymphoid lineages. Furthermore, der(1;18)(q10;q10) might play some role in the appearance of an additional myeloid phenotype.
© 2016 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27607436     DOI: 10.1159/000448447

Source DB:  PubMed          Journal:  Cytogenet Genome Res        ISSN: 1424-8581            Impact factor:   1.636


  5 in total

1.  PHF6 and DNMT3A mutations are enriched in distinct subgroups of mixed phenotype acute leukemia with T-lineage differentiation.

Authors:  Wenbin Xiao; Maheetha Bharadwaj; Max Levine; Noushin Farnhoud; Friederike Pastore; Bartlomiej M Getta; Anne Hultquist; Christopher Famulare; Juan S Medina; Minal A Patel; Qi Gao; Natasha Lewis; Janine Pichardo; Jeeyeon Baik; Brian Shaffer; Sergio Giralt; Raajit Rampal; Sean Devlin; Robert Cimera; Yanming Zhang; Maria E Arcila; Elli Papaemmanuil; Ross L Levine; Mikhail Roshal
Journal:  Blood Adv       Date:  2018-12-11

Review 2.  An Adult Patient with Early Pre-B Acute Lymphoblastic Leukemia with t(12;17)(p13;q21)/ZNF384-TAF15.

Authors:  Nikolaos Georgakopoulos; Panagiotis Diamantopoulos; Francesca Micci; Nefeli Giannakopoulou; Konstantinos Zervakis; Aglaia Dimitrakopoulou; Nora-Athina Viniou
Journal:  In Vivo       Date:  2018 Sep-Oct       Impact factor: 2.155

3.  EP300-ZNF384 fusion gene product up-regulates GATA3 gene expression and induces hematopoietic stem cell gene expression signature in B-cell precursor acute lymphoblastic leukemia cells.

Authors:  Akinori Yaguchi; Takeshi Ishibashi; Kazuki Terada; Hitomi Ueno-Yokohata; Yuya Saito; Junya Fujimura; Toshiaki Shimizu; Kentaro Ohki; Atsushi Manabe; Nobutaka Kiyokawa
Journal:  Int J Hematol       Date:  2017-04-04       Impact factor: 2.490

4.  Clinical Characteristics And Outcome Of Biphenotypic Acute Leukemia: 10 Case Reports And Literature Review.

Authors:  Jifeng Yu; Yingmei Li; Haizhou Xing; Yue Pan; Hui Sun; Dingming Wan; Yanfang Liu; Xinsheng Xie; Chong Wang; Ling Sun; Kai Sun; Zhongxing Jiang
Journal:  Cancer Manag Res       Date:  2019-10-31       Impact factor: 3.989

5.  TAF1 plays a critical role in AML1-ETO driven leukemogenesis.

Authors:  Ye Xu; Na Man; Daniel Karl; Concepcion Martinez; Fan Liu; Jun Sun; Camilo Jose Martinez; Gloria Mas Martin; Felipe Beckedorff; Fan Lai; Jingyin Yue; Alejandro Roisman; Sarah Greenblatt; Stephanie Duffort; Lan Wang; Xiaojian Sun; Maria Figueroa; Ramin Shiekhattar; Stephen Nimer
Journal:  Nat Commun       Date:  2019-10-29       Impact factor: 14.919

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.